Cited by 884Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Petitjean, A, Achatz, M I W, Borresen-Dale, A L, Hainaut, P, Olivier, M·2007·Oncogene

Open this paper in CoChat — free account

Abstract

A large amount of data is available on the functional impact of missense mutations in TP53 and on mutation patterns in many different cancers. New data on mutant p53 protein function, cancer phenotype and prognosis have recently been integrated in the International Agency for Research on Cancer TP53 database (http://www-p53.iarc.fr/). Based on these data, we summarize here current knowledge on the respective roles of mutagenesis and biological selection of mutations with specific functional characteristic in shaping the patterns and phenotypes of mutations observed in human cancers. The main conclusion is that intrinsic mutagenicity rates, loss of transactivation activities, and to a lesser extent, dominant-negative activities are the main driving forces that determine TP53 mutation patterns and influence tumor phenotype. In contrast, current experimental data on the acquisition of oncogenic activities (gain of function) by p53 mutants are too scarce and heterogenous to assess whether this property has an impact on tumor development and outcome. In the case of inherited TP53 mutations causing Li-Fraumeni and related syndromes, the age at onset of some tumor types is in direct relation with the degree of loss of transactivation capacity of missense mutations. Finally, studies on large case series demonstrate that TP53 mutations are independent markers of bad prognosis in breast and several other cancers, and that the exact type and position of the mutation influences disease outcome. Further studies are needed to determine how TP53 haplotypes or loss of alleles interact with mutations to modulate their impact on cancer development and prognosis.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1210302

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“191117) encodes a transcription factor which is activated in response to several forms of cellular stress and exerts multiple, antiproliferative functions (Vogelstein et al., 2000).”
Background
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559

Flagged first, then by citations

Show all 117 references

Research works printed but not linked: 1

Langerod A, Burdette L, Yeager M, Llaca V, Presswalla S, Gerhard DS et al. (2006a). Pattern of genetic variation in the tp53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79. Hum Mutat (in press).

Sorted by citations

Items 201–300 of 883

Arsenic Trioxide Reactivates Proteasome-Dependent Degradation of Mutant p53 Protein in Cancer Cells in Part via Enhanced Expression of Pirh2 E3 Ligase
Yan, W., Jung, Y.-S., Zhang, Y., & Chen, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103497 · Cited by 53
Overview of the genetic basis toward early detection of breast cancer
Silva, S. D., Tennekoon, K. H., & Karunanayake, E. H. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s185870 · Cited by 56
Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer
Johnson, J. L., Pillai, S., & Chellappan, S. (2012) · Biochemistry Research International · doi:10.1155/2012/940405 · Cited by 52
Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423
Kashiyama, T., Oda, K., Ikeda, Y., Shiose, Y., Hirota, Y., Inaba, K., Makii, C., Kurikawa, R., Miyasaka, A., Koso, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087220 · Cited by 51
Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells
Hosain, S. B., Khiste, S., Uddin, M. B., Vorubindi, V., Ingram, C., Zhang, S., Hill, R. A., Gu, X., & Liu, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11169 · Cited by 53
High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling
Bastien, R. R. L., Lewis, T. B., Hawkes, J. E., Quackenbush, J. F., Robbins, T. C., Palazzo, J., Perou, C. M., & Bernard, P. S. (2008) · Human Mutation · doi:10.1002/humu.20726 · Cited by 50
Anti‐leukaemic effects induced by APR‐246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells
Ali, D., Mohammad, D. K., Mujahed, H., Jonson‐Videsäter, K., Nore, B., Paul, C., & Lehmann, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14036 · Cited by 49
Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1α
Lee, Y.-M., Lim, J.-H., Chun, Y., Moon, H.-E., Lee, M. K., Huang, E. L., & Park, J. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp196 · Cited by 49
Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage
Zerdoumi, Y., Lanos, R., Raad, S., Flaman, J., Bougeard, G., Frébourg, T., & Tournier, I. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx106 · Cited by 52
Genome-Wide Association Studies in Glioma
Kinnersley, B., Houlston, R. S., & Bondy, M. L. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-1080 · Cited by 48
A novel signature derived from immunoregulatory and hypoxia genes predicts prognosis in liver and five other cancers
Chang, W. H., Forde, D., & Lai, A. G. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1775-9 · Cited by 47
Relationship between p53 status and the bioeffect of ionizing radiation (Review)
Kong, X., Yu, D., Wang, Z., & Li, S. (2021) · Oncology Letters · doi:10.3892/ol.2021.12922 · Cited by 53
TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 53
Arsenite induced poly(ADP-ribosyl)ation of tumor suppressor P53 in human skin keratinocytes as a possible mechanism for carcinogenesis associated with arsenic exposure
Komissarova, E. V., & Rossman, T. G. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.014 · Cited by 48
Mutant p53 Promotes Tumor Cell Malignancy by Both Positive and Negative Regulation of the Transforming Growth Factor β (TGF-β) Pathway
Ji, L., Xu, J., Liu, J., Amjad, A., Zhang, K., Liu, Q., Zhou, L., Xiao, J., & Li, X. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.639351 · Cited by 47
The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes
Zhang, L., Padron, E., & Lancet, J. E. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.10.006 · Cited by 47
Frequent Mutations in EGFR, KRAS and TP53 Genes in Human Lung Cancer Tumors Detected by Ion Torrent DNA Sequencing
Cai, X., Sheng, J., Tang, C., Nandakumar, V., Ye, H., Ji, H. L., Tang, H., Yu, Q., Guan, H., Lou, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095228 · Cited by 47
Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death
Narayanan, K. B., Ali, M., Barclay, B. J., Cheng, Q. S., D'Abronzo, L. S., Dornetshuber-Fleiss, R., Ghosh, P., Guzman, M. J. G., Lee, T. J., Leung, P. S., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv032 · Cited by 50
Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers
Darcy, K. M., Brady, W. E., McBroom, J. W., Bell, J. G., Young, R. C., McGuire, W. P., Linnoila, R. I., Hendricks, D. T., Bonome, T., & Farley, J. H. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.020 · Cited by 47
The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas
Martínez‐Useros, J., & García‐Foncillas, J. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.02.092 · Cited by 46
Expression of Galectin-7 Is Induced in Breast Cancer Cells by Mutant p53
Campion, C. G., Labrie, M., Lavoie, G., & St‐Pierre, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072468 · Cited by 46
Loss of Transcription Factor KLF5 in the Context of p53 Ablation Drives Invasive Progression of Human Squamous Cell Cancer
Yang, Y., Nakagawa, H., Tétreault, M.-P., Billig, J., Victor, N., Goyal, A., Sepulveda, A. R., & Katz, J. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1702 · Cited by 46
Probing the Functional Impact of Sequence Variation on p53-DNA Interactions Using a Novel Microsphere Assay for Protein-DNA Binding with Human Cell Extracts
Noureddine, M., Menéndez, D., Campbell, M. R., Bandele, O. J., Horvath, M. M., Wang, X., Pittman, G. S., Chorley, B. N., Resnick, M. A., & Bell, D. A. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000462 · Cited by 45
Translating next generation sequencing to practice: Opportunities and necessary steps
Kamalakaran, S., Varadan, V., Janevski, A., Banerjee, N., Tuck, D. P., McCombie, W. R., Dimitrova, N., & Harris, L. N. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.04.008 · Cited by 46
Upregulation of SPRR3 Promotes Colorectal Tumorigenesis
Cho, D., Jo, Y. K., Roh, S. A., Na, Y.-S., Kim, T. W., Jang, S. J., Kim, Y. S., & Kim, J. C. (2010) · Molecular Medicine · doi:10.2119/molmed.2009.00187 · Cited by 45
Intratumour heterogeneity of p53 expression; causes and consequences
Xue, Y., Luis, B. S., & Lane, D. P. (2019) · The Journal of Pathology · doi:10.1002/path.5328 · Cited by 44
Inherited Cancer Syndromes in Children and Young Adults
D'Orazio, J. A. (2010) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181ced34c · Cited by 45
Inhibition of mutant Kras and p53‐driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53
Xu, D., Tong, X., Sun, L., Li, H., Jones, R., Liao, J., & Yang, G. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23097 · Cited by 44
Enhancement of transcriptional activity of mutant p53 tumor suppressor protein through stabilization of tetramer formation by calix[6]arene derivatives
Kamada, R., Yoshino, W., Nomura, T., Chuman, Y., Imagawa, T., Suzuki, T., & Sakaguchi, K. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.053 · Cited by 43
KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma
Sinn, B. V., Striefler, J. K., Rudl, M., Lehmann, A., Bahra, M., Denkert, C., Sinn, M., Stieler, J., Klauschen, F., Budczies, J., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000077 · Cited by 43
Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon‐V600 mutations in cutaneous melanoma patients
Kim, D. W., Haydu, L. E., Joon, A. Y., Bassett, R. L., Siroy, A. E., Tetzlaff, M. T., Routbort, M. J., Amaria, R. N., Wargo, J. A., McQuade, J. L., et al. (2016) · Cancer · doi:10.1002/cncr.30463 · Cited by 43
Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
Sajic, T., Liu, Y., Arvaniti, E., Šurinová, S., Williams, E. G., Schiess, R., Hüttenhain, R., Sethi, A., Pan, S., Brentnall, T. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.114 · Cited by 43
Design and synthesis of anticancer 1-hydroxynaphthalene-2-carboxanilides with a p53 independent mechanism of action
Spaczyńska, E., Mrozek‐Wilczkiewicz, A., Malarz, K., Kos, J., Goněc, T., Oravec, M., Gawecki, R., Bąk, A., Doháňošová, J., Kapustíková, I., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42595-y · Cited by 43
PNA Clamping in Nucleic Acid Amplification Protocols to Detect Single Nucleotide Mutations Related to Cancer
Fouz, M. F., & Appella, D. H. (2020) · Molecules · doi:10.3390/molecules25040786 · Cited by 42
Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer
Hashmi, A. A., Naz, S., Hashmi, S. K., Hussain, Z. F., Irfan, M., Khan, E. Y., Faridi, N., Khan, A., & Edhi, M. M. (2018) · BMC Clinical Pathology · doi:10.1186/s12907-018-0077-0 · Cited by 42
MicroRNAs Regulate Cell Cycle and Cell Death Pathways in Glioblastoma
Sati, I. S. E. E., & Parhar, I. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413550 · Cited by 45
ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters
Dell’Orso, S., Fontemaggi, G., Stambolsky, P., Goeman, F., Voellenkle, C., Levrero, M., Strano, S., Rotter, V., Oren, M., & Blandino, G. (2011) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2010.0084 · Cited by 44
Structural Effects of the L145Q, V157F, and R282W Cancer-Associated Mutations in the p53 DNA-Binding Core Domain
Calhoun, S., & Daggett, V. (2011) · Biochemistry · doi:10.1021/bi200192j · Cited by 42
Origins of Injection-Site Sarcomas in Cats: The Possible Role of Chronic Inflammation—A Review
Woodward, K. (2011) · ISRN Veterinary Science · doi:10.5402/2011/210982 · Cited by 42
A Supercharged Fluorescent Protein as a Versatile Probe for Homogeneous DNA Detection and Methylation Analysis
Lei, C., Huang, Y., Nie, Z., Hu, J. J., Li, L., Lu, G., Han, Y., & Yao, S. Z. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403615 · Cited by 42
So-called massive retinal gliosis: A critical review and reappraisal
Jakobiec, F. A., Thanos, A., Stagner, A. M., Grossniklaus, H. E., & Proia, A. D. (2015) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.12.002 · Cited by 42
Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
Boyarskikh, U. A., Gulyaeva, L. F., Avdalyan, A. M., Андреевич, К. А., Khrapov, E. A., Lazareva, D. G., Кушлинский, Н. Е., Melkonyan, A., Arakelyan, A., & Филипенко, М. Л. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01103 · Cited by 44
Verteporfin disrupts multiple steps of autophagy and regulates p53 to sensitize osteosarcoma cells
Saini, H., Sharma, H., Mukherjee, S., Chowdhury, S., & Chowdhury, R. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01720-y · Cited by 42
Targeting the p53 Pathway in Ewing Sarcoma
Neilsen, P. M., Pishas, K. I., Callen, D. F., & Thomas, D. M. (2010) · Sarcoma · doi:10.1155/2011/746939 · Cited by 43
Significance of TP53 mutations as predictive markers of adjuvant cisplatin‐based chemotherapy in completely resected non‐small‐cell lung cancer
Ma, X., Rousseau, V., Sun, H., Lantuéjoul, S., Filipits, M., Pirker, R., Popper, H., Mendiboure, J., Vataire, A. L., Chevalier, T. L., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.015 · Cited by 42
Self-citation
p53 Transactivation and the Impact of Mutations, Cofactors and Small Molecules Using a Simplified Yeast-Based Screening System
Andreotti, V., Ciribilli, Y., Monti, P., Bisio, A., Lion, M., Jordan, J., Fronza, G., Menichini, P., Resnick, M. A., & Inga, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020643 · Cited by 43
The Contrived Mutant p53 Oncogene – Beyond Loss of Functions
Sabapathy, K. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00276 · Cited by 45
Constructing germline research cohorts from the discarded reads of clinical tumor sequences
Gusev, A., Groha, S., Taraszka, K., Semenov, Y. R., & Zaitlen, N. (2021) · Genome Medicine · doi:10.1186/s13073-021-00999-4 · Cited by 33
Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients
Schmidt, M. K., Tommiska, J., Broeks, A., van Leeuwen, F. E., Veer, L. J. V., Pharoah, P. D., Easton, D. F., Shah, M., Humphreys, M. K., Dörk, T., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2460 · Cited by 41
The role of TP53 gain-of-function mutation in multifocal glioblastoma
Olafson, L. R., Gunawardena, M. P., Nixdorf, S., McDonald, K. L., & Rapkins, R. W. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03318-5 · Cited by 40
p53 and Hereditary Cancer
Merino, D. M., & Malkin, D. M. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_1 · Cited by 39
BRCA1 and p53 Tumor Suppressor Molecules in Alzheimer’s Disease
Nakanishi, A., Minami, A., Kitagishi, Y., Ogura, Y., & Matsuda, S. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16022879 · Cited by 41
Differential Analysis of Ovarian and Endometrial Cancers Identifies a Methylator Phenotype
Kolbe, D. L., DeLoia, J. A., Porter-Gill, P. A., Strange, M., Petrykowska, H. M., Guirguis, A., Krivak, T. C., Brody, L. C., & Elnitski, L. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032941 · Cited by 40
Role of TP53 in the progression of pre‐malignant and malignant oral mucosal lesions. A follow‐up study of 144 patients
Ogmundsdottir, H. M., Björnsson, J., & Holbrook, W. P. (2009) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2009.00766.x · Cited by 40
Signal-dependent regulation of gene expression as a target for cancer treatment: Inhibiting p38α in colorectal tumors
Chiacchiera, F., & Simone, C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.061 · Cited by 41
Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview.
Zhao, M., He, X., & Teng, X. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2016.02.05 · Cited by 40
mir-660-p53-mir-486 Network: A New Key Regulatory Pathway in Lung Tumorigenesis
Borzi, C., Calzolari, L., Centonze, G., Milione, M., Sozzi, G., & Fortunato, O. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010222 · Cited by 38
Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer
Shakya, R., Tarulli, G. A., Sheng, L., Lokman, N. A., Ricciardelli, C., Pishas, K. I., Selinger, C. I., Kohonen‐Corish, M. R. J., Cooper, W. A., Turner, A. G., et al. (2017) · Oncogene · doi:10.1038/onc.2017.66 · Cited by 42
A Supercharged Fluorescent Protein as a Versatile Probe for Homogeneous DNA Detection and Methylation Analysis
Lei, C., Huang, Y., Nie, Z., Hu, J. J., Li, L., Lu, G., Han, Y., & Yao, S. (2014) · Angewandte Chemie · doi:10.1002/ange.201403615 · Cited by 40
p53mutations associated with aging-related rise in cancer incidence rates
Richardson, R. B. (2013) · Cell Cycle · doi:10.4161/cc.25494 · Cited by 41
p53 talks to PARP: the increasing complexity of p53-induced cell death
Wiman, K. G. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.111 · Cited by 39
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients
Dufour, A. M., Palermo, G., Zellmeier, E., Mellert, G., Duchâteau-Nguyen, G., Schneider, S., Benthaus, T., Kakadia, P. M., Spiekermann, K., Hiddemann, W., et al. (2013) · Blood · doi:10.1182/blood-2012-10-458695 · Cited by 39
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
Fountzilas, G., Giannoulatou, E., Alexopoulou, Z., Zagouri, F., Timotheadou, E. T., Papadopoulou, K., Lakis, S., Bobos, M., Poulios, C., Sotiropoulou, M. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9022 · Cited by 39
Aneuploid CTC and CEC
Lin, P. P. (2018) · Diagnostics · doi:10.3390/diagnostics8020026 · Cited by 39
Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review
Panou, V., & Røe, O. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124327 · Cited by 40
Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer
Hassan, N. M. M., Tada, M., Hamada, J.-I., Kashiwazaki, H., Kameyama, T., Akhter, R., Yamazaki, Y., Yano, M., Inoue, N., & Moriuchi, T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.052 · Cited by 39
The regulatory mechanisms of oncomiRs in cancer
Otmani, K., Rouas, R., Berehab, M., & Lewalle, P. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116165 · Cited by 42
Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
Trejo‐Solís, C., Castillo‐Rodríguez, R. A., Serrano-García, N., Silva‐Adaya, D., Vargas-Cruz, S., Chávez-Cortéz, E. G., Gallardo‐Pérez, J. C., Zavala-Vega, S., Cruz-Salgado, A., & Magaña-Maldonado, R. (2024) · Metabolites · doi:10.3390/metabo14050249 · Cited by 41
miRNome of inflammatory breast cancer
Maltseva, D. V., Galatenko, V., Samatov, T. R., Zhikrivetskaya, S. O., Khaustova, N. A., Нечаев, И. Н., Shkurnikov, M. Y., Lebedev, A. E., Mityakina, I., Каприн, А. Д., et al. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-871 · Cited by 37
Comprehensive genomic profiling and prognostic analysis of cervical gastric-type mucinous adenocarcinoma
Lu, S., Shi, J., Zhang, X., Kong, F., Liu, L., Dong, X., Wang, K., & Shen, D. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03080-y · Cited by 41
Disruption of estrogen receptor α-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy
Liu, W., Ip, M. M., Podgorsak, M. B., & Das, G. M. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0044-z · Cited by 38
p53, ER, and Ki67 Expression in Canine Mammary Carcinomas and Correlation With Pathological Variables and Prognosis
Brunetti, B., Bacci, B., Angeli, C., Benazzi, C., & Muscatello, L. V. (2020) · Veterinary Pathology · doi:10.1177/0300985820973462 · Cited by 37
An Investigational Approach for the Prediction of Gastric Cancer Using Artificial Intelligence Techniques: A Systematic Review
Bhardwaj, P., Bhandari, G., Kumar, Y., & Gupta, S. (2022) · Archives of Computational Methods in Engineering · doi:10.1007/s11831-022-09737-4 · Cited by 37
Genetically Engineered Mice as Experimental Tools to Dissect the Critical Events in Breast Cancer
Menezes, M. E., Das, S. K., Emdad, L., Windle, J. J., Wang, X., Sarkar, D., & Fisher, P. B. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00008-1 · Cited by 39
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer
Bozhanov, S. S., Angelova, S. G., Krasteva, M. E., Markov, T. L., Christova, S. L., Gavrilov, I., & Georgieva, E. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0824-9 · Cited by 37
Preferential Binding of Hot Spot Mutant p53 Proteins to Supercoiled DNA In Vitro and in Cells
Brázdová, M., Navrátilová, L., Tichý, V., Němcová, K., Lexa, M., Hrstka, R., Pečínka, P., Adámik, M., Vojtěšek, B., Paleček, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059567 · Cited by 38
TIPE1 promotes cervical cancer progression by repression of p53 acetylation and is associated with poor cervical cancer outcome
Zhao, P., Pang, X., Jiang, J., Wang, L., Zhu, X., Yin, Y., Zhai, Q., Xiang, X., Feng, F., & Xu, W. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy163 · Cited by 37
CCNG1 (Cyclin G1) regulation by mutant‐P53 via induction of Notch3 expression promotes high‐grade serous ovarian cancer (HGSOC) tumorigenesis and progression
Xu, Y., Zhang, Q. H., Miao, C., Dongol, S., Li, Y., Jin, C., Dong, R., Li, Y., Yang, X., & Kong, B. (2018) · Cancer Medicine · doi:10.1002/cam4.1812 · Cited by 36
Gain-of-Function Mutations in p53 in Cancer Invasiveness and Metastasis
Roszkowska, K. A., Giziński, S., Sady, M., Gajewski, Z., & Olszewski, M. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041334 · Cited by 37
Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition
Park, J., Diefenbach, R. J., Byrne, N., Long, G. V., Scolyer, R. A., Gray, E. S., Carlino, M. S., & Rizos, H. (2021) · Cancers · doi:10.3390/cancers13071740 · Cited by 37
Modulating undruggable targets to overcome cancer therapy resistance
Passirani, C., Vessières, A., Regina, G. L., Link, W., & Silvestri, R. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100788 · Cited by 37
MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models
Fingerle‐Rowson, G., & Petrenko, O. (2007) · Cell Division · doi:10.1186/1747-1028-2-22 · Cited by 37
The nuclear factor erythroid 2-related factor 2/p53 axis in breast cancer
Fakheri, H., Sajadi, M. A., Afrashteh, A., Ma, W., Xia, L., & Valilo, M. (2023) · Biochemia Medica · doi:10.11613/bm.2023.030504 · Cited by 40
Hereditary Diffuse Gastric Cancer
Schrader, K. A., & Huntsman, D. D. (2010) · Cancer treatment and research · doi:10.1007/978-1-4419-6033-7_3 · Cited by 36
A Pathogenic Mosaic TP53 Mutation in Two Germ Layers Detected by Next Generation Sequencing
Behjati, S., Maschietto, M. C., Williams, R. D., Side, L. E., Hubank, M. J. F., West, R., Pearson, K., Sebire, N. J., Tarpey, P. S., Futreal, P. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096531 · Cited by 39
Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line
Khan, M. I., Dębski, K. J., Dąbrowski, M., Czarnecka, A. M., & Szczylik, C. A. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00138.2016 · Cited by 38
Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol
Kong, A. H., Good, J. S., Kirkham, A. J., Savage, J., Mant, R., Llewellyn, L., Parish, J. L., Spruce, R. J., Forster, M. D., Schipani, S., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033009 · Cited by 36
Comparative Oncology: New Insights into an Ancient Disease
Boddy, A. M., Harrison, T. M., & Abegglen, L. M. (2020) · iScience · doi:10.1016/j.isci.2020.101373 · Cited by 38
p53: Its Mutations and Their Impact on Transcription
Vaughan, C. A., Pearsall, I., Yeudall, W. A., Deb, S. P., & Deb, S. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_4 · Cited by 37
Modulation of the Disordered Conformational Ensembles of the p53 Transactivation Domain by Cancer-Associated Mutations
Ganguly, D., & Chen, J. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004247 · Cited by 38
TP 53 mutation and human papilloma virus status of oral squamous cell carcinomas in young adult patients
Braakhuis, B. J. M., Rietbergen, M. M., Buijze, M., Snijders, P. J. F., Bloemena, E., Brakenhoff, R. H., & Leemans, C. R. (2013) · Oral Diseases · doi:10.1111/odi.12178 · Cited by 35
The involvement of E6, p53, p16, MDM2 and Gal-3 in the clinical outcome of patients with cervical cancer
Stiasny, A., Freier, C. P., Kühn, C., Schulze, S., Mayr, D. C., Alexiou, C., Janko, C., Wiest, I., Dannecker, C., Jeschke, U., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6752 · Cited by 37
Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer
Ciani, Y., Fedrizzi, T., Prandi, D., Lorenzin, F., Locallo, A., Gasperini, P., Franceschini, G. M., Benelli, M., Elemento, O., Fava, L. L., et al. (2021) · Cell Systems · doi:10.1016/j.cels.2021.10.001 · Cited by 35
Exploring preferred amino acid mutations in cancer genes: Applications to identify potential drug targets
Anoosha, P., Sakthivel, R., & Gromiha, M. M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.11.006 · Cited by 36
Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis
Qiu, Y., Tan, M., McMeekin, S., Thai, T., Ding, K., Moore, K. N., Liu, H., & Zheng, B. (2015) · Acta Radiologica · doi:10.1177/0284185115620947 · Cited by 35
Human Umbilical Cord Matrix Stem Cells Maintain Multilineage Differentiation Abilities and Do Not Transform during Long-Term Culture
Scheers, I., Lombard, C. A., Paganelli, M., Campard, D., Najimi, M., Gala, J., Decottignies, A., & Sokal, E. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071374 · Cited by 34
Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3
Batır, M. B., Şahin, E., & Çam, F. S. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-05093-y · Cited by 36
NOP14 promotes proliferation and metastasis of pancreatic cancer cells
Zhou, B., Wu, Q., Chen, G., Zhang, T., & Zhao, Y.-P. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.010 · Cited by 34
Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology
Li, Q., Li, G., Li, P., Wang, H., Fang, X., He, T., & Li, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101155 · Cited by 35
Systematic analysis of genotype‐specific drug responses in cancer
Kim, N., He, N., Kim, C., Zhang, F., Lu, Y., Yu, Q., Stemke‐Hale, K., Greshock, J. D., Wooster, R. F., Yoon, S., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27529 · Cited by 33

Authors: Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M.
Affiliations: Centre international de recherche sur le cancer (FR)
Corresponding author: Hainaut, P
ORCID: Petitjean, A
Achatz, M I W
Hainaut, P
Olivier, M
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2007-04-02
Volume: 26
Issue: 15
Pages: 2157-2165
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1210302
OpenAlex: W2042484101
Cited by: 884
References: 117
Citations by year: 2026: 16 · 2025: 29 · 2024: 29 · 2023: 50 · 2022: 55 · 2021: 52 · 2020: 50 · 2019: 53 · 2018: 60 · 2017: 46 · 2016: 57 · 2015: 52 · 2014: 53 · 2013: 43 · 2012: 48
FWCI: 5.08
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: TP53 mutation, missense mutations, dominant-negative p53, gain-of-function, mutagenesis, tumor phenotype, cancer prognosis, Li-Fraumeni syndrome, loss of heterozygosity, breast cancer
MeSH terms: Genetic Markers, Humans, Mutation, Neoplasms, Polymorphism, Genetic, Prognosis, Biomarkers, Tumor, Tumor Suppressor Protein p53, Mutagenesis, Li-Fraumeni Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks